Last SFr.80.20 CHF
Change Today -0.35 / -0.43%
Volume 3.2M
NOVN On Other Exchanges
Symbol
Exchange
SIX Swiss Ex
Xetra
New York
OTC US
Mexico
Frankfurt
SIX Swiss Ex
As of 11:43 AM 07/23/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

James S. Shannon BSc, M.D., MRCP (UK)

Chief Medical Officer, GlaxoSmithKline plc
AgeTotal Calculated CompensationThis person is connected to 8 board members in 2 different organizations across 13 different industries.

See Board Relationships
58--

Background*

Dr. James S. Shannon, BSc, M.D., MRCP (UK) has been the Chief Medical Officer of GlaxoSmithKline plc since May 1, 2012. Dr. Shannon served as the Chief Executive Officer and President of Cerimon Pharmaceuticals, Inc., from January 2009 to April 2010. Dr. Shannon served as Global Head of Development at Novartis Pharma AG (a division within Novartis AG) from 2005 to 2008. He joined Cerimon in December 2008. Dr. Shannon served in various executive roles at Novartis AG from ...

Read Full Background

Corporate Headquarters*

Lichtstrasse 35
Basel, Basel-Stadt 4056

Switzerland

Phone: 41 61 324 11 11
Fax: --

Board Members Memberships*

Former Director
Former Member of The Board of Directors
2008-N/A
Chief Executive Officer, President and Director
2010-2012
Former Director and Member of Nomination & Remuneration Committee
2010-2012
Former Director and Chairman of Nominating & Corporate Governance Committee
2010-2012
Former Director and Member of Compensation Committee
2011-N/A
Former Director

Education*

BS 1977
Queen’s University of Belfast
MD 1986
Queen’s University of Belfast

Other Affiliations*

Annual Compensation*

There is no Annual Compensation data available.

Stock Options*

There is no Stock Options data available.

Total Compensation*

There is no Total Compensation data available.
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NOVN:VX SFr.80.20 CHF -0.35

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
John C. Martin Ph.D.Chairman and Chief Executive Officer
Gilead Sciences Inc.
$1.6M
Indra K. Nooyi M.P.P.M.Chairman and Chief Executive Officer
Pepsico, Inc.
$1.6M
Marijn E. Dekkers Ph.D.Chairman of Management Board and Chief Executive Officer
Bayer AG
€2.9M
Lars Rebien Sørensen Chief Executive Officer
Novo Nordisk A/S
kr15.2M
Christopher A. Viehbacher Chief Executive Officer, Director and Member of Strategy Committee
Sanofi
€3.0M
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVARTIS AG-REG, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.